Stockreport

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC [Yahoo! Fina...

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF Data show robust intracranial activity both in TKI naïve and pretreated settings in patients with ROS1-positive NSCLC Findings demonstrate potential of repotrectinib [Read more]